Polar Capital Global Healthcare Trust reveals top portfolio holdings

Polar Capital Global Healthcare Trust plc has disclosed its portfolio breakdown as of June 30, 2025, revealing significant concentration in pharmaceuticals (26.4%) and U.S. equities (45.7%). Key holdings include Eli Lilly & Co (6.1%), Abbott Laboratories (5.1%), and AstraZeneca (5.0%), with the top ten positions comprising 40.8% of the trust's assets. This transparency provides investors with crucial insight into the trust's strategic allocation and core exposures within the global healthcare sector.

Analysis

Polar Capital Global Healthcare Trust's portfolio composition as of June 30, 2025, reveals a concentrated strategy with its top ten holdings constituting a significant 40.8% of the portfolio. The trust is heavily weighted towards large-cap pharmaceuticals, with Eli Lilly & Co (LLY) representing the largest single position at 6.1%, followed by Abbott Laboratories (ABT) at 5.1% and AstraZeneca (AZN) at 5.0%. Sectorally, pharmaceuticals (26.4%), healthcare equipment (24.7%), and biotechnology (20.1%) dominate the allocation, indicating a clear focus on these three core healthcare segments. Geographically, the portfolio has a substantial overweight position in United States equities, which account for 45.7% of assets, complemented by a notable European exposure concentrated in Denmark (12.1%) and Switzerland (10.8%). The low cash position of 1.0% suggests the trust is almost fully invested, reflecting a confident stance from the investment manager on their current holdings.

Key Decisions for Investors

• Investors considering the trust should assess their alignment with its high-conviction bets, as the performance is heavily levered to its top holdings like Eli Lilly, Abbott, and AstraZeneca.
• The significant geographic concentration in the U.S. (45.7%) and sector focus on pharmaceuticals (26.4%) must be evaluated against an investor's own diversification and risk-management strategy.